Fondren Management’s Enzo Biochem, Inc. ENZ Stock Holding History

Fondren Management’s Portfolio ENZ Stock Details ENZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-727,000	Closed	-$1.91M	–	101
2019 Q4	$1.91M	Buy	727,000 +372,000	+105%	+$1.11M	1.96%	14
2019 Q3	$1.28M	Buy	355,000 +179,137	+102%	+$634K	1.06%	24
2019 Q2	$593K	Buy	+175,863	New	+$620K	0.56%	45

Other funds holding ENZ

HFA

Harbert Fund Advisors Birmingham, Alabama $3.03M AUM 40.55% 1-Year Est. Return

EGA

Evermore Global Advisors Summit, New Jersey $26.3M AUM 7.42% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Ariel Investments Chicago, Illinois $8.93B AUM 29.58% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Fondren Management's ENZ Position: Q1 2020 in Review

Fondren Management sold out of Enzo Biochem, Inc. (ENZ) in Q1 2020, closing a stake of 727,000 shares — an estimated $1.91M sold.

Fondren Management first reported a position in ENZ in Q2 2019 and held it in 3 quarters. The position peaked at $1.91M in Q4 2019. 76 funds tracked by Wall St. Rank hold ENZ as of Q1 2020.

Fondren Management reported no remaining Enzo Biochem, Inc. position as of Q1 2020 after selling out during the quarter.
Fondren Management sold 727,000 Enzo Biochem, Inc. shares in Q1 2020, an estimated $1.91M.
Fondren Management first reported a position in Enzo Biochem, Inc. in Q2 2019 and held it in 3 quarters.
Fondren Management's Enzo Biochem, Inc. position peaked at $1.91M in Q4 2019.
76 funds tracked by Wall St. Rank held Enzo Biochem, Inc. as of Q1 2020.

Based on Fondren Management's 13F filing for Q1 2020, filed 15 May 2020.